Stock of The Day: 7-27-20 (NASDAQ: MNOV) MediciNova, Inc. +95%

(NASDAQ: MNOV)MediciNova, Inc. 1 day chart 7/27/20


Sector: Health Technology

Industry: Biotechnology

Employees: 8

MediciNova, Inc. is a biopharmaceutical company, which engages in the acquisition and development of small molecule therapeutics for the treatment of serious diseases for the treatment of diseases with unmet medical need. Its development pipeline consists of clinical-stage compounds for the treatment of acute exacerbations of asthma and COPD, progressive multiple sclerosis, methamphetamine addiction, neuropathic pain, asthma, interstitial cystitis, and solid tumor cancers. The company was founded by Yuichi Iwaki on September 26, 2000 and is headquartered in La Jolla, CA.

Company Profile

Medicinova, Inc. is a biopharmaceutical company. The company is focused on developing small molecule therapeutics for the treatment of serious diseases with unmet medical needs. The Company is developing activities on MN-166 (ibudilast) for neurological disorders, such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction (methamphetamine dependence, opioid dependence, and alcohol dependence), and MN-001 (tipelukast) for fibrotic diseases, such as nonalcoholic steatohepatitis (NASH) and idiopathic pulmonary fibrosis (IPF). The Company’s pipeline includes MN-221 (bedoradrine) for the treatment of acute exacerbation of asthma and MN-029 (denibulin) for solid tumor cancers.

Why MediciNova’s Stock Is Trading Higher Today

MediciNova Announces SARS-CoV-2 Vaccine Joint Development with BioComo and Mie University Japan

Investor Relations Press Releases Stock of The Day: (NASDAQ: MNOV) MediciNova, Inc.

Leave a Reply

Your email address will not be published. Required fields are marked *